Skip to content
Octave Strengthens Clinical Expertise in MS and Neurodegenerative Disease –
Read the Release
For Providers
The MSDA Test Overview
Get Connected
For Patients
The MSDA Test
Billing Resources
Where Can I Get The Test?
Clinical Evidence
All Publications
Clinical Utility Study
News & Events
CMSC 2025
Clinical Webinar Dec. 2024
Media & Blog
For Providers
The MSDA Test Overview
Get Connected
For Patients
The MSDA Test
Billing Resources
Where Can I Get The Test?
Clinical Evidence
All Publications
Clinical Utility Study
News & Events
CMSC 2025
Clinical Webinar Dec. 2024
Media & Blog
Contact Us
Get In Touch
For Providers
The MSDA Test Overview
Get Connected
For Patients
The MSDA Test
Billing Resources
Where Can I Get The Test?
Clinical Evidence
All Publications
Clinical Utility Study
News & Events
CMSC 2025
Clinical Webinar Dec. 2024
Media & Blog
For Providers
The MSDA Test Overview
Get Connected
For Patients
The MSDA Test
Billing Resources
Where Can I Get The Test?
Clinical Evidence
All Publications
Clinical Utility Study
News & Events
CMSC 2025
Clinical Webinar Dec. 2024
Media & Blog
Get In Touch
For Providers
The MSDA Test Overview
Get Connected
For Patients
The MSDA Test
Billing Resources
Where Can I Get The Test?
Clinical Evidence
All Publications
Clinical Utility Study
News & Events
CMSC 2025
Clinical Webinar Dec. 2024
Media & Blog
For Providers
The MSDA Test Overview
Get Connected
For Patients
The MSDA Test
Billing Resources
Where Can I Get The Test?
Clinical Evidence
All Publications
Clinical Utility Study
News & Events
CMSC 2025
Clinical Webinar Dec. 2024
Media & Blog
Investigation of Serum Based Proteomic Biomarker Signatures Relative to Steroid Responsiveness and Disease Activity Status in Relapsing Multiple Sclerosis Patients
October 26, 2022
in
By
Ryan Delduca
Comment
No Comments
Click here